Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal

1. Johnson & Johnson acquires Intra-Cellular Therapies for $14.6 billion. 2. Acquisition includes Caplyta, effective for schizophrenia and bipolar disorder. 3. Caplyta’s FDA approval as MDD treatment could reshape market dynamics. 4. AbbVie’s emraclidine failed key trial, casting doubts on its schizophrenia potential. 5. Historical acquisitions like Bristol-Myers $14 billion deal show market trends.